Anthropic reports early results from six drug-development partnerships using Claude
Anthropic described on 27 October several months of work with six drug developers, and said all of it is at an early, mostly preclinical stage. With Enveda, Claude reviewed 1,061 pages of manufacturing documentation, caught all 11 issues that human reviewers had found and flagged seven more, cutting human review time by 89%, from over 25 hours to under three. A regulatory document it drafted in four hours, against about three months by hand, still went through standard human review, which found one minor error.
With BigHat Biosciences, about 1,010 antibody variants proposed with Claude were made and tested over roughly 10 weeks, and the best bound more than 10 times more tightly. Divergence Labs generated about 35,000 antibody designs in about a month. Anthropic also said it acquired Mithril Medicine, a one-person company working on two rare muscular dystrophies; if results hold, human trials could start as early as late 2028.
The Enveda result shows how to trust a model reviewer: compare it against issues people already found, then keep a human check at the end. Lab tests, not the model, still decide what works.
Drafted with AI from the original source, then checked and edited by Sridhar Mukkandi. Spotted a mistake? Write to hello@tarkika.com and we'll correct it here.